Rubric Capital Management (New York)’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Rubric Capital Management (New York)’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-315,277	Closed	-$1.25M	–	102
2022 Q4	$1.25M	Hold	315,277	–	–	0.05%	88
2022 Q3	$2.1M	Hold	315,277	–	–	0.11%	77
2022 Q2	$1.53M	Buy	315,277 +71,803	+29%	+$437K	0.08%	83
2022 Q1	$2.28M	Buy	+243,474	New	+$2.42M	0.08%	68

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Rubric Capital Management (New York)'s MRNS Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2023, closing a stake of 315,277 shares — an estimated $1.25M sold.

Rubric Capital Management (New York) first reported a position in MRNS in Q1 2022 and held it in 4 quarters. The position peaked at $2.28M in Q1 2022. 86 funds tracked by Wall St. Rank hold MRNS as of Q1 2023.

Rubric Capital Management (New York) reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 315,277 Marinus Pharmaceuticals, Inc shares in Q1 2023, an estimated $1.25M.
Rubric Capital Management (New York) first reported a position in Marinus Pharmaceuticals, Inc in Q1 2022 and held it in 4 quarters.
Rubric Capital Management (New York)'s Marinus Pharmaceuticals, Inc position peaked at $2.28M in Q1 2022.
86 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.